The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells.

ABSTRACT:

Purpose

This study focused on combining irinotecan with poly(ADP-ribose) polymerase (PARP) inhibitors to explore the potential for novel combination therapeutics in small cell lung cancer (SCLC).

Materials and methods

We selected 10 different SCLC cell lines with diverse mutational backgrounds in DNA damage response (DDR) pathway genes to evaluate the efficacy of the combination of three PARP inhibitors and irinotecan. After the cells were exposed to the drugs for 7 days, cell viability was measured, and a combination index was calculated. Apoptotic signaling was assessed via western blot, and DNA damage was evaluated using an alkaline comet assay.

Results

We assessed the synergistic effects of PARP inhibitors and irinotecan in in vitro SCLC models, which revealed inc

SUBMITTER: Oh S 

PROVIDER: S-EPMC12527629 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature